82°

Topics

U.S. Securities and Exchange Commission
Allergan questions viability, experience of would-be buyer Valeant
Allergan questions viability, experience of would-be buyer Valeant

A day before would-be buyer Valeant Pharmaceuticals is set to unveil a second, unsolicited takeover bid, its acquisition target, Allergan Inc., sought to discredit the company by filing a presentation with regulators questioning the viability of Valeant's business strategy.  Valeant Pharmaceuticals International Inc., the Canadian company, recently teamed up with activist investor Bill Ackman in an attempt to take over Allergan, the Irvine company whose best-selling product is Botox, the popular wrinkle treatment.  It offered to pay $46 billion in cash and stock last month for Allergan, but the Botox maker rejected the offer earlier this month, criticizing it for being too...

Loading